Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Merck
Dow
AstraZeneca
Boehringer Ingelheim

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Clazakizumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Clazakizumab?

Clazakizumab is an investigational drug.

There have been 4 clinical trials for Clazakizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2019.

The most common disease conditions in clinical trials are Asthma, Arthritis, Rheumatoid, and Arthritis. The leading clinical trial sponsors are Vitaeris INC, ICON Clinical Research, and Medical University of Vienna.

There are three US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for Clazakizumab
TitleSponsorPhase
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyNational Heart, Lung, and Blood Institute (NHLBI)Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyUniversity of North Carolina, Chapel HillPhase 2
Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) DeclineICON Clinical ResearchPhase 3

See all Clazakizumab clinical trials

Clinical Trial Summary for Clazakizumab

Top disease conditions for Clazakizumab
Top clinical trial sponsors for Clazakizumab

See all Clazakizumab clinical trials

US Patents for Clazakizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Clazakizumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Clazakizumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Clazakizumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Clazakizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Clazakizumab Argentina 108097 2036-04-04   Start Trial
Clazakizumab Australia 2017246228 2036-04-04   Start Trial
Clazakizumab Brazil 112018070214 2036-04-04   Start Trial
Clazakizumab Canada 3019137 2036-04-04   Start Trial
Clazakizumab Chile 2018002803 2036-04-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Mallinckrodt
Colorcon
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.